BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Telegram Restored on Apple App Store After Temporary Removal 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
OXFORD, United Kingdom, and CAMBRIDGE, Mass., April 05, 2018 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on 10 April 2018 at 3:00pm CEST in Monte Carlo, Monaco.
A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer | ||
| Panmure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
| Freddy Crossley, Corporate Finance | ||
| Tom Salvesen, Corporate Broking | ||
| MacDougall Biomedical Communications (US) | Tel: | +1 781 235 3060 |
| Karen Sharma | [email protected] | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Jessica Hodgson / | [email protected] | |
| Philippa Gardner |
